Bedaquiline plus delamanid for XDR tuberculosis

The Lancet Infectious Diseases

Volumn 16, Issue 3, 2016, Pages 294-

  Lachâtre, Marie ^a,b   Rioux, Christophe ^a   DÛ, Damien Le ^c   Fréchet Jachym, Mathilde ^c   Veziris, Nicolas ^d,e,f   Bouvet, Elisabeth ^a,b   Yazdanpanah, Yazdan ^a,b,g  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Hôpital de Bligny   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f France   (France)

^g UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; LINEZOLID; NITROIMIDAZOLE DERIVATIVE; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; CASE REPORT; COMBINATION CHEMOTHERAPY; ELECTROCARDIOGRAPHY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LETTER; LUNG LOBECTOMY; MALE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; PRIORITY JOURNAL; YOUNG ADULT; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HEALTH CARE DELIVERY;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; NITROIMIDAZOLES; OXAZOLES;

EID: 84959241751     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)00047-5     Document Type: Letter

References (2)

1. Reed C, Mason L, Cox H, Seaworth B, Lessem E, Furin J Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis 2015, 15:1131.
2. Matteelli A, D'Ambrosio L, Centis R, Tadolini M, Migliori GB Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis 2015, 15:1131-1132.